Peramivir was recently approved by the FDA for the treatment of acute uncomplicated influenza A literature review published in the journal Infection and Drug Resistance discusses the role of peramivir ...
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has ...
BIRMINGHAM, Ala., Sept. 19 -- BioCryst Pharmaceuticals, Inc. today announced preliminary findings from a Phase II study with intramuscular (i.m.) injection of peramivir, the Company's product ...
In the peramivir arm, the median time to alleviation of combined influenza symptoms was 79 hours compared with 100 hours in the oseltamivir arm. The Food and Drug Administration (FDA) has expanded the ...
BIRMINGHAM, Ala., Jan. 23 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the ...
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude ...
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised ...
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised ...
St. Jude study shows intramuscular injection of peramivir for 8 days protected mice from lethal H5N1 influenza virus infection and inhibited virus replication, supporting the use of this drug to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results